Drugs / NNC4004-0002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06859073 | Nov 2024 → Jun 2026 overdue | — | Novo Nordisk A/S | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC4004-0002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06859073 ↗ |
| Route | Subcutaneous | “NNC4004-0002 will be given as a single ascending dose via subcutaneous route.” NCT06859073 ↗ |